Literature DB >> 17625938

Chronic relapsing opsoclonus-myoclonus syndrome: combination of cyclophosphamide and dexamethasone pulses.

B Wilken1, M Baumann, C G Bien, B Hero, K Rostasy, F Hanefeld.   

Abstract

Opsoclonus-myoclonus syndrome (OMS) is a rare and debilitating disorder of unknown etiology affecting children and adults. Outcome is unfavourable; approximately 80% of children with OMS suffer from mild to severe neurological handicaps, mainly cognitive impairment. A standard therapy does not exist. Due to the possible immune-mediated mechanisms, treatment with steroids, ACTH, plasmapheresis and immunoglobulins can be successful. However, some children become steroid dependent and symptoms may reoccur after treatment has been finished. We present two girls with OMS, who had a prolonged clinical course lasting 4 and 9 years with many relapses. Both children developed symptoms around the age of two years. Diagnostic work-up to exclude neuroblastoma was negative. Several treatment modalities including oral steroids, dexamethasone pulses, immunoglobulin and cyclosporine were used without lasting success. In addition, cognitive impairment developed in both children. In order to prevent further clinical and mental deterioration, 6 pulses of cyclophosphamide in combination with dexamethasone pulses every 4 weeks were administered. Both children showed significant improvement of OMS symptoms. One girl is still symptom free 18 months after treatment, mild ataxia developed in the other after 12 months. Both children are mentally handicapped and in special need schools. We conclude that combination of cyclophosphamide pulses and dexamethasone pulse therapy is a therapeutic option even after a long clinical course to improve symptoms of OMS.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17625938     DOI: 10.1016/j.ejpn.2007.05.005

Source DB:  PubMed          Journal:  Eur J Paediatr Neurol        ISSN: 1090-3798            Impact factor:   3.140


  6 in total

1.  Paraneoplastic brain stem encephalitis.

Authors:  Franz Blaes
Journal:  Curr Treat Options Neurol       Date:  2013-04       Impact factor: 3.598

2.  Adult-onset opsoclonus-myoclonus-ataxia syndrome as a manifestation of brazilian lyme disease-like syndrome: a case report and review of literature.

Authors:  Angelina Maria Martins Lino; Raphael Ribeiro Spera; Fernando Peixoto Ferraz de Campos; Christian Henrique de Andrade Freitas; Márcio Ricardo Taveira Garcia; Leonardo da Costa Lopes; Aleksander Snioka Prokopowitsch
Journal:  Autops Case Rep       Date:  2014-03-31

3.  Demographic, Clinical, and Immunologic Features of 389 Children with Opsoclonus-Myoclonus Syndrome: A Cross-sectional Study.

Authors:  Michael R Pranzatelli; Elizabeth D Tate; Nathan R McGee
Journal:  Front Neurol       Date:  2017-09-11       Impact factor: 4.003

4.  Opsoclonus-myoclonus syndrome with severe clinical course and beneficial outcome: A case report.

Authors:  Ewa Koziorowska-Gawron; Magdalena Koszewicz; Joanna Bladowska; Maria Ejma; Slawomir Budrewicz
Journal:  Medicine (Baltimore)       Date:  2021-04-09       Impact factor: 1.817

Review 5.  Update on opsoclonus-myoclonus syndrome in adults.

Authors:  Sun-Young Oh; Ji-Soo Kim; Marianne Dieterich
Journal:  J Neurol       Date:  2018-11-27       Impact factor: 4.849

6.  Opsoclonus-myoclonus syndrome attributable to West Nile encephalitis: a case report.

Authors:  Victoria Bîrluţiu; Rareş Mircea Bîrluţiu
Journal:  J Med Case Rep       Date:  2014-06-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.